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It has been widely proposed that signaling by mammalian target of rapamycin (mTOR) is both necessary and sufficient
for the induction of skeletal muscle hypertrophy. Evidence for this hypothesis is largely based on studies that used
stimuli that activate mTOR via a phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB)-dependent mechanism.
However, the stimulation of signaling by PI3K/PKB also can activate several mTOR-independent growth-promoting
events; thus, it is not clear whether signaling by mTOR is permissive, or sufficient, for the induction of hypertrophy.
Furthermore, the presumed role of mTOR in hypertrophy is derived from studies that used rapamycin to inhibit mTOR;
yet, there is very little direct evidence that mTOR is the rapamycin-sensitive element that confers the hypertrophic
response. In this study, we determined that, in skeletal muscle, overexpression of Rheb stimulates a PI3K/PKB-
independent activation of mTOR signaling, and this is sufficient for the induction of a rapamycin-sensitive hypertrophic
response. Transgenic mice with muscle specific expression of various mTOR mutants also were used to demonstrate that
mTOR is the rapamycin-sensitive element that conferred the hypertrophic response and that the kinase activity of mTOR
is necessary for this event. Combined, these results provide direct genetic evidence that a PI3K/PKB-independent
activation of mTOR signaling is sufficient to induce hypertrophy. In summary, overexpression of Rheb activates mTOR
signaling via a PI3K/PKB-independent mechanism and is sufficient to induce skeletal muscle hypertrophy. The hyper-
trophic effects of Rheb are driven through a rapamycin-sensitive (RS) mechanism, mTOR is the RS element that confers
the hypertrophy, and the kinase activity of mTOR is necessary for this event.
INTRODUCTION
Skeletal muscles make up 40–50% of the body’s mass, and
they are not only the motors that drive locomotion, but they
also play a crucial role in whole body metabolism (Lee et al.,
2000; Izumiya et al., 2008). Accordingly, it has been well
recognized that the maintenance of skeletal muscle mass
contributes significantly to disease prevention and issues
associated with the quality of life (Seguin and Nelson, 2003).
Skeletal muscle mass is known to be regulated by a vari-
ety of different stimuli, including mechanical loads, neural
activity, cytokines, growth factors, and hormones; however,
the molecular mechanisms that regulate these changes re-
main poorly defined (Frost and Lang, 2007; Sandri, 2008).
Nevertheless, our knowledge of these mechanisms is ad-
vancing, and recent studies have revealed that adaptive
changes in muscle mass are often correlated with the activity
of a protein kinase called the mammalian target of rapamy-
cin (mTOR). For example, hypertrophy resulting from in-
creased mechanical loading and 2-andrenergic agonists is
associated with an increase in mTOR signaling, whereas
atrophy resulting from disuse, glucocorticoids, and food
deprivation is associated with a decrease in mTOR signaling
(Wu et al.; Baar and Esser, 1999; Hornberger et al., 2001;
Lewis et al., 2006; Kline et al., 2007).
Several studies have not only shown that mTOR signaling
is correlated with changes in muscle mass, but in many
cases, it also has been suggested that signaling through
mTOR is necessary for these changes to occur. For example,
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hypertrophy induced by mechanical loading, insulin-like
growth factor 1 (IGF-1) and constitutively active protein
kinase B (c.a.-PKB) has been shown to be significantly, if not
completely, blocked by the mTOR inhibitor rapamycin (Bod-
ine et al., 2001; Park et al., 2005; Sandri, 2008). Because
rapamycin is considered to be a specific inhibitor of mTOR,
many have concluded that mTOR is the rapamycin-sensitive
element that confers the hypertrophic effects of these stimuli
(Davies et al., 2000; Bodine, 2006; Nader, 2007). However,
like most pharmacological inhibitors, rapamycin can exert
nonspecific (mTOR-independent) actions. For example,
rapamycin can bind and sequester the FKBP12 protein, and
the FKBP12 protein has been shown to play an important
role in the function of the ryanodine receptor and signaling
by members of the transforming growth factor- superfam-
ily (e.g., myostatin) (Avila et al., 2003; Wang and Donahoe,
2004; Osman et al., 2009). Furthermore, systemic administra-
tion of rapamycin would be expected to inhibit mTOR sig-
naling in all cells throughout the body, and therefore, it is
not clear if the anti-hypertrophic effects of rapamycin are
due specifically to inhibition of mTOR signaling in skeletal
muscle cells. Hence, it can be argued that there is strong
evidence to support the conclusion that signaling through a
rapamycin-sensitive mechanism is necessary for the hyper-
trophic effects of stimuli such as IGF-1, c.a.-PKB, and me-
chanical loads, but there is very little direct evidence that
mTOR is the rapamycin-sensitive element, in skeletal mus-
cle, that confers the hypertrophic response (Park et al., 2005).
As mentioned, mTOR is a protein kinase, and mTOR has
been shown to phosphorylate a variety of molecules impli-
cated in the regulation of muscle mass. The specific sub-
strates that mTOR phosphorylates depends on whether
mTOR is bound to the proteins raptor or rictor (Efeyan and
Sabatini, 2010). When bound to raptor, mTOR forms a rapa-
mycin-sensitive signaling complex called mTORC1, and sig-
naling by mTORC1 has been reported to be directly acti-
vated by the Ras homologue enriched in brain (Rheb) (Yang
et al., 2006; Sato et al., 2009). When activated by Rheb,
mTORC1 can phosphorylate substrates such as the threo-
nine 389 residue of the ribosomal S6 kinase (p70S6k) (Yang et
al., 2006). In contrast, when mTOR is bound to rictor it forms
the mTORC2 complex, and mTORC2 phosphorylates dis-
tinct substrates from that of mTORC1 (Efeyan and Sabatini,
2010). One of the most commonly recognized mTORC2 sub-
strates is the serine 473 residue of protein kinase B (PKB), and
unlike signaling by mTORC1, signaling by the mTORC2 is not
activated by Rheb or inhibited by rapamycin (Hresko and
Mueckler, 2005; Sarbassov et al., 2005; Efeyan and Sabatini,
2010). Thus, if mTOR is the rapamycin-sensitive element that
confers the hypertrophic effects of stimuli such as IGF-1, c.a.-
PKB, and mechanical loads, then this is probably due to sig-
naling by mTOR when it is in the mTORC1 complex.
During the past two decades it has become clear that very
low concentrations of rapamycin (2–5 nM) block mTORs
ability to phosphorylate mTORC1 substrates such as p70S6k
(Price et al., 1992). Consequently, it has been widely assumed
that rapamycin exerts its growth inhibitory actions by block-
ing the ability of mTOR to phosphorylate downstream sub-
strates (i.e., mTOR regulates growth through a kinase-de-
pendent mechanism). However, even moderately high
concentrations of rapamycin (1 M) do not inhibit mTOR’s
intrinsic kinase activity (Isotani et al., 1999; Oshiro et al.,
2004). Hence, a rapamycin-sensitive event does not neces-
sarily imply an mTOR kinase dependent event. For example,
rapamycin has been shown to inhibit myogenesis, and ex-
pression of either a rapamycin-resistant mutant of mTOR
(RR-mTOR) or rapamycin-resistant kinase-dead mutant of
mTOR (RRKD-mTOR) can rescue myogenesis from the in-
hibitory effects of rapamycin (Erbay and Chen, 2001). In
other words, myogenesis occurs through a rapamycin-sensi-
tive mechanism and mTOR is the rapamycin-sensitive element
that confers myogenesis, but surprisingly, mTOR kinase activ-
ity is not required for this event. This important observation
demonstrates that caution should be exercised before assuming
that the growth inhibitory effects of rapamycin are due to
inhibition of mTOR’s ability to phosphorylate downstream
substrates. To date, we are not aware of any in vivo studies that
have determined whether mTOR kinase activity is necessary
for the hypertrophic effects of stimuli such as IGF-1, c.a.-PKB
and mechanical loads; thus, the role of mTOR kinase activity in
these events remains to be defined.
Signaling through mTOR has not only been implicated as
being necessary but also has been implicated as being sufficient
for the induction of skeletal muscle hypertrophy. For example,
IGF-1 has been shown to induce mTOR signaling through a
pathway involving phosphatidylinositol 3-kinase (PI3K) and
protein kinase B (PKB) [IGF-13 PI3K/PKB3 mTOR] (Rom-
mel et al., 2001; Laviola et al., 2007). IGF-1 also has been shown
to induce myotube hypertrophy, and this effect is significantly
blocked by rapamycin (Rommel et al., 2001; Park et al., 2005).
Furthermore, overexpression of c.a.-PKB activates mTOR sig-
naling and induces muscle fiber hypertrophy through a rapa-
mycin-sensitive mechanism (Bodine et al., 2001; Pallafacchina et
al., 2002; Izumiya et al., 2008). Together, these observations
have led many to conclude that the activation of mTOR sig-
naling is sufficient to induce hypertrophy (Bodine et al., 2001;
Nader, 2007). However, recent studies have shown that the
activation of PI3K/PKB by IGF-1 and c.a.-PKB also can affect a
variety of mTOR-independent growth regulatory molecules
such as the glycogen synthase kinase 3, tuberin, and the
FOXO transcription factors (Frost and Lang, 2007; Sandri, 2008;
Hamilton et al., 2009). Hence, it is very possible that signaling
by mTOR is permissive, rather than sufficient, for the induction
of hypertrophy. In fact, the activation of mTOR signaling can
induce a negative feedback loop that impairs signaling by PKB,
and based on this point, it has recently been argued that a
PI3K/PKB-independent activation of mTOR may not be suffi-
cient for the induction of skeletal muscle hypertrophy (Ham-
ilton et al., 2009). Thus, the overall goal of this study was to
determine whether a PI3K/PKB-independent activation of
mTOR signaling, in skeletal muscle, is sufficient to induce
hypertrophy, and determine whether mTOR kinase activity is
necessary for this event.
MATERIALS AND METHODS
Materials
Insulin (Humalog) was purchased from Eli Lilly (Indianapolis, IN). Rabbit anti-
laminin antibodies and wortmannin were purchased from Sigma-Aldrich (St.
Louis, MO). Anti-total p70S6k, anti-green fluorescent protein (GFP), anti-total
mTOR, anti-phospho-mTOR(2481), anti-total PKB, anti-phospho-PKB(473), anti-
phospho-PKB(308), anti-Rheb, anti-total S6, and anti-phospho-S6(Ser235/236)
antibodies were purchased from Cell Signaling Technology (Danvers, MA).
Anti-phospho-p70S6k(389), tetramethylrhodamine B isothiocyanate (TRITC)-con-
jugated anti-rabbit, and fluorescein isothiocyanate (FITC)-conjugated anti-rat
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Peroxidase-conjugated anti-rabbit and peroxidase-conjugated anti-rat antibodies
were purchased from Vector Laboratories (Burlingame, CA). Rat anti-hemagglu-
tinin (HA) antibodies were purchased from Roche (Madison, WI).
Plasmid Constructs and Purification
pEGFP-C3 (GFP) was purchased from Clontech (Mountain View, CA). pRK5-
myc-p70S6K-glutathione transferase (GST p70S6k) has been described previously
(Miyazaki and Esser, 2009) and was kindly provided by Dr. Karyn Esser (Uni-
versity of Kentucky, Lexington, KY). pCDNA3-HA-Rheb (HA-Rheb) has been
described previously (Li et al., 2004) and was a generous gift from Dr. Kun-Liang
Guan (University of California–San Diego, La Jolla, CA). The dual-luciferase
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bicistronic reporter of cap-dependent translation has been described previously
(Carter and Sarnow, 2000) and was kindly provided by Dr. Sunnie Thompson
(University of Alabama, Birmingham, AL). All plasmid DNA was grown in
DH5 Escherichia coli, purified with an Endofree plasmid kit (QIAGEN, Valencia,
CA), and resuspended in sterile phosphate-buffered saline (PBS).
Cell Culture and Transfection
C2C12 myoblasts were cultured in growth media consisting of high glucose
DMEM (Hyclone Laboratories, Logan, UT) supplemented with antibiotics
and antimycotics (100 U/ml penicillin G, 100 g/ml streptomycin, and 0.25
g/ml amphotericin) and 10% fetal bovine serum (Invitrogen, Carlsbad, CA).
Lipofectamine 2000 (Invitrogen) was used to transfect 425,000 suspended
C2C12 myoblasts with 4 g of GFP or 4 g of HA-Rheb, with or without 0.2
g of GST p70S6k. The transfected myoblasts were plated on one well of a
six-well dish and grown for 48 h in antibiotic/antimycotic-free growth media.
After 48 h, the myoblasts were switched to serum-free high-glucose DMEM for
2 h before being subjected to experimental treatments. All cell culture experi-
ments were performed in a humidified 95% air, 5% CO2 incubator at 37°C.
Animals
All animal experiments in this study followed protocols approved by the
Animal Care and Use Committee at the University of Wisconsin–Madison.
FVB mice with human skeletal actin driven expression of a FLAG-tagged
rapamycin-resistant (Ser2035Thr) mutant of mTOR (RR-mTOR) or a FLAG
tagged rapamycin-resistant kinase dead (Ser2035Thr/Asp2357Glu) mutant of
mTOR (RRKD-mTOR) have been described previously (Ge et al., 2009). These
transgenic mice were bred with wild-type FVB mice and the transgenic
offspring were maintained as hemizygotes. Genotypes were confirmed with
tail snips by PCR, and 8- to 10-wk-old female offspring were used.
Skeletal Muscle Transfection (Electroporation)
Mice were anesthetized with 100 mg/kg ketamine plus 10 mg/kg xylazine,
and a small incision was made through the skin covering the tibialis anterior
(TA) muscle. A 27-gauge needle was used to inject plasmid DNA solution (2.5
g/l GFP or HA-Rheb, with or without 0.17 g/l GST p70S6k) into the
proximal (6 l) and distal (6 l) ends of the muscle belly. After the injections,
electric pulses were applied through two stainless steel pin electrodes (1-cm gap;
Harvard Apparatus, Holliston, MA) laid on top of the proximal and distal
myotendinous junctions. Eight 20-ms square-wave electric pulses at a frequency
of 1 Hz were delivered with an ECM 830 electroporation unit (BTX; Harvard
Apparatus) at a field strength of 180 V/cm. After the electroporation procedure,
the incision was closed with Vetbond surgical glue (Henry Schein, Melville, NY).
Rapamycin Injections
Rapamycin was purchased from LC laboratories (Woburn, MA) and was
dissolved in dimethyl sulfoxide (DMSO) to generate a 5 g/l stock solution.
The appropriate volume of the stock solution needed to inject mice with 1
mg/kg body weight was dissolved in 200 l of PBS. For the vehicle control
condition, mice were injected with an equivalent amount of DMSO dissolved
in 200 l of PBS. Immediately after the electroporation procedure, vehicle or
rapamycin solutions were administered via intraperitoneal injections, and
these injections were repeated every 24 h for up to 7 d.
Sample Preparation for Immunoprecipitations and
Western Blot Analysis
On collection, skeletal muscles were immediately frozen in liquid nitrogen.
Frozen muscles were homogenized with a Polytron homogenizer for 20 s in
ice-cold buffer A (40 mM Tris, pH 7.5, 1 mM EDTA, 5 mM EGTA, 0.5% Triton
X-100, 25 mM -glycerophosphate, 25 mM NaF, 1 mM Na3VO4, 10 g/ml
leupeptin, and 1 mM phenylmethylsulfonyl fluoride), and the whole homog-
enate was used for further analysis. For cell culture experiments, myoblasts
were lysed in the ice cold buffer A, centrifuged at 500  g for 5 min, and the
supernatant was used for further analysis. Sample protein concentration was
determined with a DC protein assay kit (Bio-Rad Laboratories, Hercules, CA),
and unless otherwise noted (e.g., immunoprecipitation), equivalent amounts
of protein from each sample were dissolved in Laemmli buffer and subjected
to Western blot analysis as described below.
Immunoprecipitation
Immunoprecipitation of FLAG-tagged mTOR was performed as described
previously (Hornberger et al., 2007). In brief, whole muscle homogenates were
centrifuged at 8200 g for 10 min, and 500 g of protein from the supernatant
was diluted to a volume of 1 ml with fresh ice-cold buffer A. This sample was
then incubated with 40 l of EZview red ANTI-FLAG M2 agarose affinity gel
beads (Sigma-Aldrich) with gentle rocking at 4°C for 2 h. After the incubation,
the beads were pelleted by centrifugation at 8200  g for 30 s and washed
with fresh ice-cold buffer A. After four washes, the pellets were dissolved in
2 Laemmli buffer containing no dithiothreitol and heated to 100°C for 5 min.
The beads were again pelleted by centrifugation at 8200  g for 30 s, and the
supernatant was subjected to Western blot analysis as described below.
Western Blot Analysis
Western blot analyses were performed as described previously (O’Neil et al.,
2009). In brief, samples were subjected to electrophoretic separation on SDS-
PAGE acrylamide gels. After electrophoretic separation, proteins were trans-
ferred to a polyvinylidene difluoride membrane, blocked with 5% powdered
milk in Tris-buffered saline and 1% Tween 20 (TBST) for 1 h, and then
incubated overnight at 4°C with primary antibody dissolved in TBST con-
taining 1% bovine serum albumin (BSA). After an overnight incubation, the
membranes were washed for 30 min in TBST and then probed with a perox-
idase-conjugated secondary antibody for 1 h at room temperature. After 30
min of washing in TBST, the blots were developed on film using regular
enhanced chemiluminescence (ECL) reagent (Pierce Chemical, Rockford, IL)
or ECL Plus reagent (GE Healthcare, Little Chalfont, Buckinghamshire,
United Kingdom). Once the appropriate image was captured, the membranes
were stained with Coomassie Blue to verify equal loading in all lanes. Den-
sitometric measurements were carried out using the public domain NIH
Image program (ImageJ) developed at the National Institutes of Health and
available at http://rsb.info.nih.gov/nih-image/.
Measurement of Cap-dependent Translation
TA muscles were cotransfected with 30 g of plasmid DNA encoding either
HA-Rheb or GFP and 5 g of plasmid DNA encoding a dual-luciferase
bicistronic reporter of cap-dependent translation. At 48 h after transfection,
TA muscles were collected, frozen in liquid nitrogen, and stored at 80°C
until further analysis. For this analysis, muscles were homogenized with a
Polytron homogenizer in passive lysis buffer (Promega, Madison, WI), and
Renilla and firefly luciferase activity in 25 g of sample protein was measured
with a FLUOstar Optima luminometer (BMG Labtech, Durham, NC) by using
the Dual-Luciferase Reporter Assay kit (Promega) as described in the manu-
facturer’s instructions.
Figure 1. Overexpression of Rheb induces mTOR signaling
through a PI3K-independent mechanism in skeletal muscle myo-
blasts. C2C12 myoblasts were transfected with GFP or cotransfected
with a combination of GFP and GST-tagged p70S6k (GST p70S6k) or
HA-Rheb and GST p70S6k. At 48 h after transfection, the myoblasts
were switched to serum-free media for 2 h and then incubated with
500 nM wortmannin or the solvent vehicle (DMSO) for an addi-
tional 25 min. Where indicated, the myoblasts were stimulated with
100 nM insulin during the final 10 min of this incubation period.
Cell lysates were subjected to Western blot analysis with the indi-
cated antibodies. The ratio of GST P-p70S6K(389) to total GST p70S6K
(GST P-p70/Total GST p70) was calculated and is expressed as a
percentage of the drug treatment control samples (vehicle, GFP 
GST p70S6K or wortmannin, GFP  GST p70S6K). Values are the
mean  SEM, n  4–6/group. *, significantly different from drug
treatment control.
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Immunohistochemical Analysis
Muscles were excised and placed at resting length in ice-cold PBS containing
4% paraformaldehyde. The samples were gently rocked in this solution at 4°C
for 30 min and then submerged in optimal cutting temperature compound
(Tissue-Tek, Sakura, Torrance, CA) and frozen in liquid nitrogen-chilled
isopentane. Cross sections (10 m in thickness) from the midbelly of the
muscle were obtained with a cryostat and fixed in 20°C acetone for 10 min.
Sections were warmed to room temperature for 5 min and then rehydrated
with cool steam vapors. Under gentle rocking, the rehydrated sections were
incubated in PBS for 15min followed by a 20-min incubation in a solution B
(PBS containing 0.5% BSA and 0.5% Triton X-100). Sections were then incu-
bated with the indicated primary antibodies dissolved in solution B for 1 h at
room temperature. Sections were washed with PBS and then incubated with
the appropriate fluorophore-conjugated secondary antibodies dissolved in
solution B for 1 h at room temperature. Finally, the sections were washed with
PBS and mounted with Vectashield mounting media (Vector Laboratories,
Burlingame, CA) and a coverslip. Transfected fibers (HA or GFP positive) and
laminin, phospho-S6, or total S6 were identified in dual-fluorescent images
and captured with a DS-QiMc camera on an 80i epi-fluorescence microscope
(both from Nikon, Tokyo, Japan) with FITC and TRITC cubes, respectively.
The monochrome images were merged with NIS Elements D image analysis
software (Nikon), and the staining intensity or cross-sectional area (CSA) of
35–100 randomly selected transfected and nontransfected fibers per sample
was measured by tracing the periphery of individual fibers. All analyses were
performed by investigators that were unaware of the sample identification.
Statistical Analysis
All values are expressed as means  SEM. Statistical significance was deter-
mined by using analysis of variance, followed by Student–Newman–Keuls
post hoc analysis or Dunn’s procedure for planned comparisons. Differences
between groups were considered significant if p 0.05. All statistical analyses
were performed on SigmaStat software (Systat Software, San Jose, CA).
RESULTS
Overexpression of Rheb Induces mTOR Signaling through
a PI3K-independent Mechanism in Skeletal Muscle
Myoblasts
To accomplish the goal of this study, overexpression of Rheb
was used as a means to induce a PI3K/PKB-independent
activation of mTOR signaling. Rheb was selected for this
Figure 2. Overexpression of Rheb induces an increase in the phosphorylation and total amount of the ribosomal S6 protein in vivo. Mouse
TA muscles were transfected with GFP (A–C and H–J) or HA-Rheb (D–F and K–M). At 7 d after transfection, the muscles were collected, and
cross sections from the midbelly of the muscle were subjected to immunohistochemistry for GFP or HA-Rheb and the ribosomal S6 protein
phosphorylated on the Ser235/236 residues (P-S6) (A–F) or total S6 protein (H–M). Gray scale images of the signal for GFP (B and I), HA-Rheb
(E and L), P-S6 (C and F), or total S6 (J and M). The staining intensity of P-S6 (G) or total S6 (N) in GFP-transfected fibers (black bars) and
HA-Rheb–transfected fibers (gray bars) was expressed relative to the values obtained in nontransfected fibers from the same section and is
plotted on a histogram. Values indicate the mean  SEM, n  3 muscles (230–240 transfected and 200 nontransfected fibers)/group.
*, significantly different from the values obtained in GFP-transfected fibers, p  0.05.
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study because previous reports have consistently shown
Rheb to be one of the most proximal activators of mTOR
signaling (Sun et al., 2008; Avruch et al., 2009). Furthermore,
studies in nonskeletal muscle cells have shown that Rheb
activates mTOR through a PI3K/PKB-independent mecha-
nism (Garami et al., 2003; Tee et al., 2003). To confirm that
this mechanism is conserved in skeletal muscle cells, C2C12
myoblasts were cotransfected with Rheb and GST-tagged
p70S6k (GST p70S6k) or GFP and GST p70S6k as a control
condition. At 48 h after transfection, the samples were col-
lected and changes in the phosphorylation of GST p70S6k on
the threonine 389 residue [GST p70S6k(389)] were evaluated
as a marker of mTOR signaling (Hornberger et al., 2007). The
results indicated that overexpression of Rheb induces a sig-
nificant increase in mTOR signaling in skeletal muscle myo-
blasts (Figure 1).
To determine whether the Rheb induced mTOR signaling
through a PI3K-dependent mechanism, the PI3K inhibitor
wortmannin was used. As a positive control from signaling
through PI3K, myoblasts were stimulated with insulin in the
presence or absence of wortmannin. Numerous studies have
shown that insulin activates mTOR signaling through a PI3K-
dependent mechanism (Avruch et al., 2006). Consistent with
these studies, it was determined that wortmannin com-
pletely blocked the insulin-induced increase in mTOR
signaling (Figure 1; Avruch et al., 2006). This observation
verified that wortmannin successfully inhibited PI3K-de-
pendent signaling; however, wortmannin did not inhibit the
Rheb-induced increase in mTOR signaling (Figure 1). To-
gether, these results indicate that overexpression of Rheb
induces mTOR signaling through a PI3K-independent
mechanism in C2C12 myoblasts.
Overexpression of Rheb Induces mTOR Signaling through
a PI3K/PKB-independent Mechanism in Skeletal Muscle
In Vivo
To determine whether the overexpression of Rheb could in-
duce mTOR signaling in adult skeletal muscle in vivo, mouse
TA muscles were transfected with Rheb, or GFP as a control
condition, and the phosphorylation of the ribosomal S6 (S6)
protein on the Ser235/236 residues (P-S6) was evaluated as a
marker of mTOR signaling. As shown in Figure 2, Rheb-trans-
fected fibers revealed a significantly greater amount of P-S6
compared with GFP-transfected fibers (Figure 2, A–G). It also
was determined that Rheb-transfected fibers had a slightly, yet
significantly, greater amount of total S6 protein compared with
GFP-transfected fibers (Figure 2, H–N).
In a separate series of experiments, TA muscles were
cotransfected with Rheb and GST p70S6k or GFP and GST
p70S6k as a control condition. Similar to our findings in
C2C12 myoblasts, the results indicated that overexpression
of Rheb and insulin stimulation were both sufficient to in-
duce an increase in the threonine 389 phosphorylation of
GST p70S6k (Figure 3, A and B). Furthermore, the high
transfection efficiency of our in vivo procedure, coupled
with the 26-kDa size difference between GST p70S6k and
endogenous p70S6k, allowed us to demonstrate that the
overexpression of Rheb induced a significant increase in the
threonine 389 phosphorylation of endogenous p70S6k (Fig-
ure 3, A and C). However, unlike the effects of insulin, over-
expression of Rheb did not significantly alter the phosphory-
lation of endogenous PKB on either the threonine 308 residue
[P-PKB(308)] or the serine 473 residue [P-PKB(473)] (Figure 3,
A, D, and E). Numerous studies have shown that the activation
of PI3K results in an increase in PKB(308) phosphorylation
(Vanhaesebroeck and Alessi, 2000; Hawkins et al., 2006).
Figure 3. Overexpression of Rheb induces
mTOR signaling through a PI3K/PKB-inde-
pendent mechanism in skeletal muscle in vivo.
(A–E) Mouse TA muscles were transfected
with GFP or cotransfected with a combination
of GFP and GST tagged p70S6k (GST p70S6k) or
HA-Rheb and GST p70S6k. (A) At 48 h after
transfection, the muscles were collected, and
lysates were subjected to Western blot analysis
with the indicated antibodies. Note that the
analyses were performed on both GST p70S6k
and the endogenous proteins. (B–E) In muscles
cotransfected with GST p70S6k, the phos-
phorylated to total protein ratio for GST
P-p70S6K(389) (B), endogenous P-p70S6K(389)
(C), endogenous P-PKB(308) (D), and endoge-
nous P-PKB(473) (E) was calculated and is ex-
pressed as a percentage of the values obtained
in the control samples (GFP  GST p70S6k).
Values are the mean  SEM, n  3–5/group.
*, significantly different from control, p  0.05.
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Thus, the lack of an effect of Rheb on PKB(308) phosphory-
lation suggests that, similar to the results obtained in C2C12
myoblasts, overexpression of Rheb induces mTOR signaling
through a PI3K-independent mechanism in adult skeletal
muscle in vivo. Furthermore, the serine 473 residue on PKB
has been reported to be directly phosphorylated by the
mTORC2 complex (Hresko and Mueckler, 2005; Sarbassov et
al., 2005; Guertin et al., 2006). Hence, the lack of an effect of
Rheb on PKB(473) phosphorylation suggests that overex-
pression of Rheb did not induce mTORC2 signaling, which
is consistent with previous in vitro and cell culture studies
that have shown that Rheb exclusively activates signaling by
the mTORC1 complex (Yang et al., 2006; Sato et al., 2009).
Thus, when combined, these data indicate that overexpres-
sion of Rheb induces mTOR signaling through a PI3K/PKB-
independent mechanism in adult skeletal muscle in vivo and
that the effects of Rheb on mTOR seem to be specific to the
mTORC1 complex.
Overexpression of Rheb Induces an Increase in
Cap-dependent Translation in Skeletal Muscle In Vivo
It has been proposed that activation of mTOR signaling can
induce skeletal muscle hypertrophy, in part, by promoting
an increase in the rate of protein synthesis (Bodine, 2006;
Hamilton et al., 2009). The majority of protein synthesis is
thought to occur through a cap-dependent mechanism (Ma-
honey et al., 2009); therefore, we set out to determine
whether overexpression of Rheb could induce an increase in
cap-dependent translation. In these experiments, muscles
were cotransfected with GFP or Rheb and a dual-luciferase
bicistronic reporter of cap-dependent translation (Carter and
Sarnow, 2000). As described in Figure 4A, this reporter
contains both the Renilla luciferase gene (REN) and firefly
luciferase gene (FF). The expression of REN is controlled by
cap-dependent translation, whereas the expression of FF is
controlled by cap-independent translation via the internal
ribosomal entry site (IRES) from the encephalomyocarditis
virus (EMCV). The results from these experiments indicate
that Rheb induced a significant increase in the expression of
both the cap-dependent and cap-independent translation
reporters (Figure 4B). More importantly, Rheb induced a
significant increase in the ratio of the cap-dependent to
cap-independent reporters, suggesting that Rheb induces an
increase in cap-dependent translation (Figure 4C).
Overexpression of Rheb Induces Skeletal Muscle
Hypertrophy In Vivo
To determine whether the overexpression of Rheb is suffi-
cient for the induction of skeletal muscle hypertrophy,
mouse TA muscle were transfected with HA-Rheb or GFP as
a control condition. The muscles were collected at 7 d after
transfection, and the average CSA of the transfected and
nontransfected fibers from each muscle was determined.
The results indicated that in muscles transfected with GFP,
the average CSA of the transfected and nontransfected fibers
was not significantly different (Figure 5, A, B, and E). In
muscles transfected with HA-Rheb, the average CSA of HA-
Rheb-transfected fibers was 64% greater than that of the
nontransfected fibers (Figure 5, C–E). Similar results also
were obtained when muscles were transfected with a yellow
fluorescent protein-tagged variant of Rheb (Supplemental
Figure 1). Furthermore, the CSA of HA-Rheb-transfected fibers
were significantly larger than that of GFP-transfected fibers
(Figure 5E). Combined, these results indicate that overexpres-
sion of Rheb is sufficient for the induction of skeletal muscle
hypertrophy. In addition, it also was determined that the av-
erage CSA of the nontransfected fibers from GFP and HA-Rheb
muscles was not significantly different (Figure 5E). This obser-
vation indicates that the hypertrophic effects of Rheb were
exerted in a cell autonomous manner.
Overexpression of Rheb Induces Hypertrophy via an
mTOR-dependent Mechanism That Requires mTOR
Kinase Activity
To define the role of mTOR in the Rheb-induced hypertro-
phic response, transgenic mice that express a FLAG-tagged
rapamycin-resistant (Ser2035Thr) mutant of mTOR (RR-
mTOR) or a FLAG tagged rapamycin-resistant kinase dead
(Ser2035Thr/Asp2357Glu) mutant of mTOR (RRKD-mTOR)
were used. These mice have been described by Ge et al.
(2009), and in these mice, the expression of the transgene is
under the control of the human skeletal actin promoter. As
expected, expression of the transgene could not be detected
in the liver or kidneys from these mice (data not shown).
However, total mTOR expression in skeletal muscles from
the RR-mTOR and RRKD-mTOR was significantly higher
than that observed in wild-type mice (Figure 6, A and B,
Note: these values result from a combination of both endo-
genously expressed wild-type mTOR and the transgenically
expressed RR-mTOR or RRKD-mTOR). Furthermore, FLAG
immunoprecipitates from skeletal muscle samples con-
firmed that both the RR-mTOR and RRKD-mTOR mice, but
not wild-type mice, expressed a FLAG-tagged variant of
mTOR. Moreover, phosphorylation of the Ser2481 residue
on mTOR (an mTOR autophosphorylation site) could easily
be detected on the FLAG-immunoprecipitated mTOR from
Figure 4. Overexpression of Rheb induces an increase in cap-
dependent translation in skeletal muscle in vivo. (A) Structure of the
bicistronic reporter used for measuring cap-dependent translation
of REN and EMCV IRES (i.e., cap-independent) translation of FF. (B
and C) Mouse TA muscles were cotransfected with a combination of
the bicistronic reporter and HA-Rheb or GFP as a control condition.
At 48 h after transfection, the muscles were collected and luciferase
activities were measured by a dual-luciferase assay. (B) Measurements
of the relative light units (RLU) produced by REN and FF luciferase per
milligram of total muscle protein. (C) Ratio of cap-dependent transla-
tion (REN) to cap-independent translation (FF) is expressed as a per-
centage of the values obtained in GFP transfected muscles. Values are
the mean  SEM, n  5–7/group. *, significantly different from the
values obtained in GFP-transfected muscles.
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RR-mTOR, but not RRKD-mTOR, mice (Figure 6A; Peterson
et al., 2000). Consequently, the ratio of Ser2481 phosphory-
lated mTOR to total mTOR in muscles from RRKD-mTOR,
but not RR-mTOR mice, was significantly reduced (Figure
6C). Combined, these results indicated that 1) the RR-mTOR
and RRKD-mTOR mice possessed the appropriate tissue
specific expression of the transgenes, 2) the expressed
RRKD-mTOR lacked kinase activity, and 3) the ratio of
kinase active mTOR to total mTOR was significantly re-
duced in muscles from the RRKD-mTOR mice.
The RR-mTOR and RRKD-mTOR transgenes both contain
the Ser2035Thr mutation, and this mutation has been shown
previously to render mTOR resistant to the inhibitory effects
of rapamycin (Brown et al., 1995). To confirm that expression
of mTOR containing the Ser2035Thr mutation conferred
rapamycin resistance, TA muscles from wild-type, RR-
mTOR, and RRKD-mTOR mice were cotransfected with
Rheb and GST p70S6k. Immediately after the cotransfection,
the mice were subjected to daily injections of rapamycin or
the solvent vehicle and then assessed for changes in GST
p70S6k(389) phosphorylation after 48 h. The results demon-
strated that rapamycin eliminated GST p70S6k(389) phos-
phorylation in muscles from wild-type, but not RR-mTOR,
mice (Figure 6D). Thus, these results demonstrated that phos-
phorylation of the threonine 389 residue on GST p70S6k is
regulated by a rapamycin-sensitive mechanism and that ex-
pression of mTOR with Ser2035Thr mutation was able to res-
cue this event from the inhibitory actions of rapamycin. Fur-
thermore, mTOR has been reported previously to be the kinase
that phosphorylates p70S6k on the threonine 389 residue (Horn-
berger et al., 2007). Consistent with this conclusion, GST
p70S6k(389) phosphorylation was significantly lower in vehicle-
treated RRKD-mTOR mice and could not be detected in mus-
cles from rapamycin treated RRKD-mTOR mice (Hornberger et
al., 2007). Thus, the results from this series of experiments
establish that the RR-mTOR and RRKD-mTOR transgenic mice
conveyed the appropriate phenotypes.
The RR-mTOR and RRKD-mTOR mice were then used to
determine whether Rheb induced hypertrophy through an
mTOR-dependent mechanism and whether mTOR kinase ac-
tivity was necessary for this event. Specifically, TA muscles
from wild-type, RR-mTOR, and RRKD-mTOR were trans-
fected with Rheb, and then the mice were subjected to daily
injections of rapamycin or the solvent vehicle as a control
condition. The muscles were collected at 7 d after transfection,
and the average CSA of the transfected and nontransfected
fibers was determined. The results from these experiments
demonstrated that rapamycin blocked the hypertrophic effects
of Rheb in wild-type and RRKD-mTOR, but not RR-mTOR,
mice (Figure 7). Combined, these results indicate that 1) Rheb
induces hypertrophy through a rapamycin-sensitive mecha-
nism, 2) mTOR is the rapamycin-sensitive element in skeletal
muscle that confers Rheb-induced hypertrophy, and 3) mTOR
kinase activity is necessary for the Rheb-induced hypertrophic
response.
DISCUSSION
The results of this study indicate that a PI3K/PKB-indepen-
dent activation of mTOR signaling, in skeletal muscle, is
Figure 5. Overexpression of Rheb induces
skeletal muscle fiber hypertrophy in vivo.
Mouse TA muscles were transfected with GFP
(A and B) or HA-Rheb (C and D). At 7 d after
transfection, the muscles were collected, and
cross sections from the midbelly of the muscle
were subjected to immunohistochemistry for
GFP and laminin (A) or HA-Rheb and laminin
(C). (B and D) The CSA of transfected fibers
(green bars) and nontransfected fibers (black
bars) from GFP- (B) and HA-Rheb–transfected
muscles (D) was determined and plotted on a
histogram (n  330–360 transfected and 330–
360 nontransfected fibers/group). (E) Average
CSA of the transfected () and nontransfected
() fibers in GFP- and HA-Rheb–transfected
muscles. Values are the mean  SEM, n  4
muscles/group. *, significantly different from
nontransfected fibers in HA-Rheb–transfected
muscles; †, significantly different from GFP-
transfected fibers, p  0.05.
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sufficient to induce hypertrophy. This conclusion is func-
tionally significant because it has been shown that some
physiologically relevant types of growth-promoting stimuli
induce mTOR signaling through a PI3K/PKB-independent
mechanism. For example, mechanical loads have been
shown to induce mTOR signaling through a PI3K/PKB-
independent mechanism, and it has been widely proposed,
although never demonstrated, that the mechanical load in-
duced activation of mTOR signaling is sufficient to induce
hypertrophy (Hornberger et al., 2004; Bodine, 2006; Horn-
berger et al., 2006). Based on the results of this study, it
would seem that this hypothesis is correct.
The results of this study not only demonstrate that a
PI3K/PKB-independent activation of mTOR signaling is suf-
ficient to induce hypertrophy but also demonstrate that
mTOR kinase activity is necessary for this event. This obser-
vation raises questions about the identity of the downstream
substrates through which mTOR induces hypertrophy. Al-
though the identity of these specific substrates remains to be
fully defined, it is important to consider that hypertrophy
results from a net positive change in the balance between
protein synthesis and protein breakdown, and mTOR has
been implicated in the regulation of both of these processes
(Bodine, 2006; Mahoney et al., 2009; Jung et al., 2010). For
example, mTOR has been shown to phosphorylate several
proteins that control the rate of translation (Mahoney et al.,
2009). Thus, the activation of mTOR signaling might pro-
mote hypertrophy, in part, by inducing the phosphorylation
of substrates that enhance translational efficiency. In support
of this possibility, we determined that overexpression of
Rheb induced a 33% increase in ratio of cap-dependent to
cap-independent translation (Figure 4).
Previous studies have not only shown that mTOR can
regulate protein synthesis through the control of translation
efficiency, but there is also substantial evidence that mTOR
can regulate protein synthesis by controlling translational
capacity (i.e., ribosome biogenesis) (Mahoney et al., 2009).
For example, mTOR has been shown to bind to the promoter
region of rDNA, and this occurs through a rapamycin-sen-
sitive mechanism (Tsang et al., 2010). Furthermore, mTOR
has been reported to phosphorylate several factors impli-
cated in the regulation of rDNA transcription such as UBF
and TIF-1A (Mahoney et al., 2009). Hence, activation of
mTOR signaling might promote hypertrophy by inducing
an increase in protein synthesis via both enhanced transla-
tional efficiency and translational capacity. In support of this
possibility, we have observed that Rheb transfected fibers
express a 1.7-fold greater amount of the ribosomal S6 protein
compared with nontransfected fibers of the same muscle
(Figure 2, F–J). Furthermore, the results in Figure 4 not only
revealed that overexpression of Rheb induces an increase in
the expression ratio of cap-dependent to cap-independent
translation reporters but also revealed that overexpression
of Rheb induced a large increase in the total expression of
Figure 6. Confirmation of the phenotypes in
RR-mTOR and RRKD-mTOR transgenic mice.
(A) TA muscles from wild-type, RR-mTOR, and
RRKD-mTOR mice were collected, and whole
muscle lysates were subjected directly to Western
blot analysis or subjected to immunoprecipiation
(I.P.) for the FLAG-tag followed by Western blot
analysis with the indicated antibodies. (B and C)
Quantification of total mTOR (B) and the ratio of
P-mTOR(2481) to total mTOR (C) in whole mus-
cle lysates. The data are expressed as a percent-
age of the values obtained in wild-type muscles.
*, significantly different from wild type, p  0.05.
(D) TA muscles from wild-type, RR-mTOR and
RRKD-mTOR mice were cotransfected with HA-
Rheb and GST p70S6k. Immediately after trans-
fection, mice were subjected to a regime of daily
vehicle or 1 mg/kg rapamycin injections. At 48 h
after transfection, the muscles were collected,
and lysates were subjected to Western blot anal-
ysis with the indicated antibodies. The ratio of
GST P-p70S6K(389) to total GST p70S6K (GST
P-p70/Total GST p70) was calculated and ex-
pressed as a percentage of the values obtained in
wild-type vehicle-treated samples. Values are the
mean  SEM, n  3–5/group. *, significantly
different from wild-type vehicle-treated samples,
p  0.05. ND, not detected.
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both reporters. This observation is consistent with an in-
crease in translational capacity; therefore, it seems likely that
a PI3K/PKB-independent activation of mTOR signaling in-
duces hypertrophy by promoting an increase in protein
synthesis via both enhanced translational efficiency and
translational capacity.
As mentioned, mTOR also has been implicated in the
regulation of protein degradation. For example, rapamycin
has been shown to induce lysosomal protein degradation via
autophagy, and this seems to be at least partly due to a
decrease in the phosphorylation of two key regulators of
autophagy, Atg13 and ULK1 (Jung et al., 2010). Furthermore,
mTOR phosphorylates Atg13 and ULK1 through a rapam-
ycin-sensitive mechanism, and overexpression of Rheb has
been shown to induce Atg13 and ULK1 phosphorylation
with a concomitant inhibition of autophagy (Wang et al.,
2009; Jung et al., 2010). Thus, there are several lines of
evidence that indicate that mTOR can phosphorylate and
consequently inhibit substrates that regulate lysosomal pro-
tein degradation. In addition, there is also evidence that
signaling by mTOR can regulate protein degradation by
controlling the expression of ubiquitin ligases such as Atro-
gin 1 (Herningtyas et al., 2008). Based on these points, we
propose that a PI3K/PKB-independent activation of mTOR
induces hypertrophy by regulating the phosphorylation of
substrates that promote an increase in protein synthesis (trans-
lational efficiency and capacity) and a decrease in protein deg-
radation. Further study is needed to evaluate the relative con-
tributions, both individually and in combination, of each of
these proposed aspects of mTOR-mediated hypertrophy.
In summary, a better understanding of the molecular
mechanisms that regulate muscle mass is required for the
Figure 7. Overexpression of Rheb induces hypertrophy via an mTOR-dependent mechanism that requires mTOR kinase activity. TA
muscles from wild-type mice (A and B), RR-mTOR mice (C and D), and RRKD-mTOR mice (E and F) were transfected with HA-Rheb.
Immediately after transfection, the mice were subjected to a regime of daily vehicle (A, C, and E) or 1 mg/kg rapamycin (Rap) injections (B,
D, and F). At 7 d after transfection, the muscles were collected and cross-sections from the midbelly of the muscle were subjected to
immunohistochemistry for HA-Rheb (green) and laminin (red). Histograms of the relative CSA for transfected fibers (green bars) and
nontransfected fibers (black bars) are shown to the right of each image (n  210–340 transfected and 210–340 nontransfected fibers/group).
(G) Average relative CSA of the transfected () and nontransfected () fibers for each of the conditions described in A–F. Values are the mean 
SEM, n  4–5 muscles (210–340 fibers)/group. *, significantly different from the nontransfected fibers within a given condition, p  0.05.
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development of therapies that can attenuate or prevent the
loss of muscle mass during conditions such as aging, disuse,
or neuromuscular disease. In this study, we demonstrate
that the overexpression of Rheb induces mTOR signaling
through a PI3K/PKB-independent mechanism and that this
event is sufficient to induce a robust and cell autonomous
hypertrophic response. Furthermore, it was determined that
the hypertrophic effects of Rheb occurred through a rapam-
ycin-sensitive mechanism, that mTOR was the rapamycin-
sensitive element in skeletal muscle that conferred the hy-
pertrophic response, and that the kinase activity of mTOR
was necessary for this event. Combined, these results
strongly indicate that a PI3K/PKB-independent activation of
mTOR signaling, in skeletal muscle, is sufficient to induce
hypertrophy. Thus, the results of this study fill several key
gaps in our knowledge of the molecular mechanisms that
regulate skeletal muscle mass and also provide evidence
that the development of mTOR-specific agonists could serve
as a therapeutic strategy for preventing muscle atrophy.
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